Latest Pharmaceutical Industry Performance News

Page 1 of 1

CSL Reports $8.3B Revenue, Advances Transformation, Maintains FY26 Outlook

CSL Limited has released its half-year results showing a slight revenue decline amid ongoing transformation efforts, while maintaining its full-year guidance and expanding its share buyback program.

Ada Torres

11 Feb 2026

Browse the archive

Full archive

Aug 2026 July 2026 June 2026 May 2026 Apr 2026 Mar 2026 Feb 2026 Jan 2026